Therapeutic EUS Registry
Launched by METHODIST HEALTH SYSTEM · Feb 8, 2022
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is a prospective, observational, medical chart review. There will be a retrospective chart review for patients who underwent endoscopic suturing procedures from October 2014 - May 2019. Those subjects will undergo no additional tests and procedures as part of this study.
In order to validate these procedures and broaden its use beyond tertiary centers, it is crucial to understand its efficacy and success rate. The objective of the study is to evaluate retrospectively and prospectively the efficacy and safety of T-EUS procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient who has undergone clinically indicated and/or standard of care T-EUS procedures from October 2014 - May 2019
- • Any patient who will undergo clinically indicated and/or standard of care T-EUS procedures from June 2019 - June 2027
- Exclusion Criteria:
- • Any patient who has not undergone endoscopic ultrasound would be excluded from the study.
- • Below 18 years of age
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Prashant Kedia, MD
Principal Investigator
The Methodist Hospital Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials